Please login to the form below

Not currently logged in
Email:
Password:

Descovy

This page shows the latest Descovy news and features for those working in and with pharma, biotech and healthcare.

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen’s single tablet Symtuza gains NHS England funding 

Biktarvy is a combination of integrase inhibitor bictegravir with Gilead’s existing blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics